Financial Data and Key Metrics Changes - Q1 revenue was $178 million, representing a 28% year-over-year increase and a 30% sequential increase. Organic growth, excluding COVID impacts, was 7% year-over-year [16][19][20] - Non-GAAP EPS was $0.12, flat year-over-year, while GAAP EPS reported a loss of $0.15 [17][20] - Adjusted EBITDA margin was approximately 7% [17][21] Business Line Data and Key Metrics Changes - Products segment revenue totaled $90 million, with organic growth of 15% year-over-year, driven by a 23% increase in automated systems [22][23] - Services segment generated $89 million in revenue, with organic growth of 4%, led by a 10% increase in Sample Repository Solutions [24][26] - Cell and gene therapy sales grew nearly 60% year-over-year, contributing approximately 10% to total revenue [9][50] Market Data and Key Metrics Changes - The U.S. market remains a steady grower, Europe is making progress, and China showed double-digit growth in genomics despite COVID challenges [9][10] - B Medical achieved a record revenue of $42 million, although it fell short of initial expectations [10][19] Company Strategy and Development Direction - The company is focusing on accelerating investments in sales talent and innovative product development to drive growth [12][15] - A tuck-in acquisition of Ziath was completed to enhance the portfolio of high-throughput offerings [14] - The company aims to achieve low double-digit growth objectives in the second half of the fiscal year [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position and growth potential despite macroeconomic challenges [11][15] - The company anticipates that cost reduction measures will contribute to margin expansion in the second half of fiscal 2023 [18][30] Other Important Information - The company plans to return approximately $1 billion to shareholders within the calendar year, including a $500 million accelerated share repurchase program [18][27] - The balance sheet remains strong with over $1 billion in cash available for strategic investments [19][27] Q&A Session Summary Question: Guidance on revenue growth and margin expectations - Management reiterated the target of 30% revenue growth for the year but acknowledged margin pressures in the first half, expecting to achieve 10% or better EBITDA margins by Q4 [33][34] Question: Acceleration in cell and gene therapy growth - Management noted a surprising increase in growth attributed to new offerings and strong customer engagement, with a significant portion of growth coming from the genomics business [35][36] Question: Visibility in the storage part of the Sample Repository Solutions business - Management confirmed strong visibility in storage revenue growth, indicating a solid recurring revenue base as samples are stored [39][40] Question: Focus of future M&A activities - Management indicated that while recent M&A has focused on products, there is an active pipeline for genomics-related acquisitions as well [46][47] Question: Revenue contribution from cell and gene therapy - Management confirmed that cell and gene therapy now accounts for approximately 10% of total revenue, excluding B Medical [49][50] Question: Trends in genomic services customer behavior - Management observed no significant differences in spending behavior across customer segments, although academic institutions may show slightly slower spending [69][70]

Conference Call First Quarter Fiscal 2023 Financial Results February 8, 2023 1 Azenta Life Sciences | Proprietary and confidential. Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from thos ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Azenta, Inc. (NASDAQ:AZTA) Q4 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Sara Silverman - Head, IR Stephen Schwartz - CEO, President & Director Lindon Robertson - EVP & CFO Conference Call Participants Vijay Kumar - Evercore ISI David Saxon - Needham & Company Jacob Johnson - Stephens Inc. Yuan Zhi - B. Riley Securities Operator Greetings, and welcome to the Azenta Q4 2022 Financial Results. [Operator Instructions]. As a reminder, this conference is being recorded Monday ...